Vanguard Group
PRTK

Vanguard Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Vanguard Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,228,066
Closed -$4.92M – 4577
2023
Q2 		$4.92M Hold
2,228,066
– – ﹤0.01% 3310
2023
Q1 		$5.66M Buy
2,228,066
+28,918
+1% +$57.1K ﹤0.01% 3242
2022
Q4 		$4.11M Buy
2,199,148
+24,523
+1% +$61.1K ﹤0.01% 3394
2022
Q3 		$5.59M Buy
2,174,625
+154,939
+8% +$385K ﹤0.01% 3263
2022
Q2 		$3.9M Sell
2,019,686
-259,192
-11% -$566K ﹤0.01% 3510
2022
Q1 		$6.77M Buy
2,278,878
+117,105
+5% +$441K ﹤0.01% 3366
2021
Q4 		$9.71M Sell
2,161,773
-45
-0% -$213 ﹤0.01% 3224
2021
Q3 		$10.5M Buy
2,161,818
+11,297
+0.5% +$62.3K ﹤0.01% 3214
2021
Q2 		$14.7M Sell
2,150,521
-44,144
-2% -$357K ﹤0.01% 3006
2021
Q1 		$15.5M Sell
2,194,665
-21,463
-1% -$155K ﹤0.01% 2926
2020
Q4 		$13.9M Buy
2,216,128
+154,222
+7% +$908K ﹤0.01% 2823
2020
Q3 		$11.2M Buy
2,061,906
+254,754
+14% +$1.26M ﹤0.01% 2734
2020
Q2 		$9.43M Buy
1,807,152
+280,479
+18% +$1.25M ﹤0.01% 2802
2020
Q1 		$4.81M Buy
1,526,673
+147,791
+11% +$545K ﹤0.01% 2989
2019
Q4 		$5.56M Buy
1,378,882
+31,045
+2% +$108K ﹤0.01% 3135
2019
Q3 		$5.82M Sell
1,347,837
-254,910
-16% -$1.02M ﹤0.01% 3082
2019
Q2 		$6.39M Buy
1,602,747
+501,177
+45% +$2.38M ﹤0.01% 3079
2019
Q1 		$5.9M Buy
1,101,570
+485,256
+79% +$3.13M ﹤0.01% 3080
2018
Q4 		$3.16M Sell
616,314
-775,730
-56% -$5.89M ﹤0.01% 3238
2018
Q3 		$13.5M Buy
1,392,044
+43,816
+3% +$442K ﹤0.01% 2773
2018
Q2 		$13.8M Buy
1,348,228
+171,779
+15% +$1.94M ﹤0.01% 2741
2018
Q1 		$15.3M Buy
1,176,449
+230,519
+24% +$3.43M ﹤0.01% 2606
2017
Q4 		$16.9M Buy
945,930
+1,174
+0.1% +$24.5K ﹤0.01% 2559
2017
Q3 		$23.7M Buy
944,756
+77,140
+9% +$1.8M ﹤0.01% 2410
2017
Q2 		$20.9M Buy
867,616
+143,316
+20% +$3.17M ﹤0.01% 2431
2017
Q1 		$13.9M Buy
724,300
+63,121
+10% +$995K ﹤0.01% 2605
2016
Q4 		$10.2M Buy
661,179
+85,562
+15% +$1.11M ﹤0.01% 2737
2016
Q3 		$7.49M Buy
575,617
+147,689
+35% +$1.96M ﹤0.01% 2812
2016
Q2 		$5.95M Buy
427,928
+63,885
+18% +$941K ﹤0.01% 2892
2016
Q1 		$5.52M Buy
364,043
+12,777
+4% +$195K ﹤0.01% 2909
2015
Q4 		$6.66M Buy
351,266
+16,942
+5% +$323K ﹤0.01% 2848
2015
Q3 		$6.35M Buy
334,324
+23,922
+8% +$596K ﹤0.01% 2858
2015
Q2 		$8M Buy
310,402
+84,015
+37% +$2.38M ﹤0.01% 2785
2015
Q1 		$7.08M Buy
226,387
+7,633
+3% +$219K ﹤0.01% 2822
2014
Q4 		$8.43M Buy
218,754
+184,841
+545% +$4.41M ﹤0.01% 2621
2014
Q3 		$824K Buy
33,913
+6,628
+24% +$173K ﹤0.01% 3564
2014
Q2 		$652K Buy
27,285
+2,209
+9% +$72K ﹤0.01% 3614
2014
Q1 		$927K Buy
25,076
+906
+4% +$35.8K ﹤0.01% 3480
2013
Q4 		$975K Buy
24,170
+1,526
+7% +$64.8K ﹤0.01% 3420
2013
Q3 		$864K Buy
22,644
+783
+4% +$28K ﹤0.01% 3413
2013
Q2 		$792K Buy
+21,861
New +$937K ﹤0.01% 3365

Vanguard Group's PRTK Position: Q3 2023 in Review

Vanguard Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 2,228,066 shares — an estimated $4.92M sold.

Vanguard Group first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $23.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

  • Vanguard Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Vanguard Group sold 2,228,066 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $4.92M.
  • Vanguard Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
  • Vanguard Group's Paratek Pharmaceuticals, Inc. position peaked at $23.7M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.